On July 1, 2025, Siemens AG officially completed its acquisition of Dotmatics, a Boston-based provider of R&D software for the life sciences, in a transaction valued at $5.1 billion. Dotmatics now sits inside Siemens’ Digital Industries Software division—an interesting placement, given that the Siemens division is traditionally devoted to design, engineering, and manufacturing software, while Dotmatics focuses squarely on life sciences.
“With Dotmatics, we’re building a new era of innovation in life sciences. From research through to production, we’re creating a unique, end-to-end digital thread: we combine Dotmatics’ scientific intelligence with our industrial AI technologies and digital twins,” said Roland Busch, President and CEO of Siemens AG. “This will allow us to help our customers accelerate breakthroughs, reduce development cycles and bring life-saving pharmaceuticals faster and more affordably to the market.”
Siemens may argue that its technology, skills, and global reach can support a life sciences software company as effectively as they support industrial software. Indeed, its Digital Industries Software arm has refined concepts such as the digital thread and digital twins, as well as implemented AI for design and engineering workflows. With the Dotmatics acquisition, Siemens gets a chance to anthropomorphize the “digital twin” concept, going from machines and factories into its namesake, a human digital twin.
About Dotmatics
Dotmatics’ flagship product is Luma, a cloud-native scientific intelligence platform.
Luma uses low code to unify and structure scientific data across instruments, applications, and workflows, creating an AI-ready foundation for discovery. It can automatically ingest data from lab equipment such as high-content imaging systems, mass spectrometers, plate readers, UV-Vis spectrophotometers, and flow cytometers. Luma then normalizes this information and produces reports, charts, and insights.
Its AI features include natural-language interaction. For example, a researcher can type:
“Show me all antibody candidates from the last six months with binding affinity stronger than 10 nM, rank them by predicted stability, highlight any with corresponding flow cytometry results, and generate a summary chart.”
That kind of query demonstrates how the platform reduces manual data wrangling and accelerates R&D. While the terms may sound foreign to many engineers, they resonate with anyone in bioengineering or medical product design.
For Siemens, the move represents a territorial expansion into life sciences—a parallel to Dassault Systèmes’ $5.8 billion acquisition of Medidata in 2019. Dassault bet on clinical trials and patient data. It was a fortuitous move for Dassault. The COVID pandemic that followed led to a high demand for clinical trials for vaccines, from which Dassault was to profit. Siemens, with Dotmatics, is betting on scientific discovery and lab data — and it may not need a future windfall. Siemens also has a ready-made customer base within its own family: Siemens Healthineers. Healthineers offers advanced digital platforms such as Syngo imaging, enterprise IT, consulting, and managed services—making it a natural complement to Dotmatics’ R&D focus.
Not Siemens’ First Healthcare Rodeo
Siemens’ 75% stake in Siemens Healthineers AG (headquarters Erlangen, Germany), a $22 billion (2022 revenue) medical imaging and diagnostics operation, confirms the company’s long-term interest in healthcare. Healthineers’ roots stretch back over 125 years, tracing its lineage to pioneering firms like Siemens & Halske and Reiniger, Gebbert & Schall, early innovators in X‑ray and medical devices.
Siemens spun off Healthineers in 2017, moving back to its manufacturing core, implying a contraction of sorts, only to expand again into healthcare/life sciences with the Dotmatics acquisition.
Good Deal?
Siemens paid 17 times Dotmatics’ annual revenue (about $300 million in 2025)—well above the traditional software acquisition benchmark of ~3 times. However, Dotmatics’ strong profitability—adjusted EBITDA margin above 40%—makes it an attractive asset.
Still, a back-of-the-envelope calculation suggests it could take decades to recoup the purchase price. Siemens’ own projections, though, call for $100 million in annual revenue synergies in the medium term, growing to over $500 million annually in the long run, which could make the acquisition pay off far faster.